ASGCT News   |   Development

Six ASGCT Members Earn Career Development Awards

ASGCT Staff - October 23, 2019

ASGCT’s Career Development Awards support independent transformative pilot studies in gene and cell therapy conducted by ASGCT members.

The American Society of Gene and Cell Therapy (ASGCT) has selected six members to receive $50,000 Career Development Awards, a total distribution of $300,000. This group of awardees is ASGCT’s second class of Career Development Award recipients, a program in which ASGCT recognizes members who are transitioning toward independence in their careers.

ASGCT’s Career Development Awards support independent transformative pilot studies in gene and cell therapy conducted by ASGCT members, particularly those ideas that would be challenging to fund with normal funding mechanisms.

ASGCT’s six awardees are a diverse group from varied and wide-ranging specialties:

Mohommadsharif Tabebordbar, Ph.D.—postdoctoral associate, Broad Institute of MIT and Harvard
Developing liver-detargeted and muscle-tropic AAV capsid variants across species

Geoffrey L. Rogers, Ph.D.—postdoctoral scholar, University of Southern California
Improved strategies for site-specific gene insertion using non-homologous end joining

Daniel L. Kiss, Ph.D.—assistant professor, Houston Methodist Research Institute
Construction of circular RNAs to block miRNA-driven oncogenic transformation

Kshitiz Singh, M.B.B.S., M.M.S.T., Ph.D.—research fellow, Children’s Hospital of Philadelphia
Development of non-viral mechanisms of targeting lung epithelial cells for prenatal gene editing in a large animal model

Christopher Nelson, Ph.D.—assistant professor, University of Arkansas
Characterizing and overcoming the host response to genome editing therapy

Kalpana Parvathaneni, MS, Ph.D.— postdoctoral researcher, Center for Cellular Immunotherapies, University of Pennsylvania
Engineered CAR-T Cells to Overcome Alloimmunity in Transplant Rejection

Congratulations to the awardees!

Share This Page

Related Articles

ASGCT News

ASGCT Education Program Returns, Covers Parkinson's Disease

ASGCT Staff - October 10, 2019
ASGCT News

Molecular Therapy Impact Factors Jump Nearly 28 Percent Across Family of Titles

ASGCT Staff - June 26, 2019
Advocacy

ASGCT Heats Up in Summer 2019

Maritza McIntyre, Ph.D. - June 14, 2019
Annual Meeting 2019

FDA Approves Zolgensma, Landmark AAV-Delivered Gene Therapy to Treat Spinal Muscular Atrophy

May 24, 2019